Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.33 CHF | +1.36% | +6.78% | +6.34% |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.34% | 199B | |
+25.61% | 660B | |
+22.79% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+13.08% | 219B | |
-9.65% | 196B | |
-8.75% | 149B | |
-5.21% | 146B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : Molecular Partners Initiate Clinical Trial For Ensovibep in COVID-19 Patients